LivaNova Upgraded to Strong-Buy as Analysts Boost Price Targets

LivaNova (NASDAQ:LIVN) has received an upgrade from Wall Street Zen, which has raised its rating from a buy to a strong-buy in a report published on Saturday morning. This positive shift reflects growing confidence among analysts regarding the company’s stock performance.

Analyst Ratings and Price Targets

Recent assessments from various financial institutions further underscore the momentum behind LivaNova’s stock. Robert W. Baird set a target price of $75.00 in a note released on Tuesday, indicating a bullish outlook. Meanwhile, the Goldman Sachs Group assigned a neutral rating with a target price of $55.00 in a report dated October 1. Mizuho has also shown optimism by increasing its target from $70.00 to $72.00 and giving the company an “outperform” rating.

On September 3, Needham & Company LLC reiterated a buy rating with a target price of $64.00. Contrarily, Weiss Ratings maintained a “sell (d+)” rating on the stock as of December 15. Overall, six analysts have rated LivaNova as a buy, two have issued hold ratings, and one has classified it as a sell. According to data from MarketBeat, the stock currently holds a consensus rating of “Moderate Buy” with a target price of $65.63.

Institutional Investments in LivaNova

Changes in institutional positions reflect increasing interest in LivaNova. GAMMA Investing LLC expanded its stake in the company by 182.5% during the second quarter, now holding 630 shares valued at approximately $28,000 after acquiring an additional 407 shares. Similarly, the State of Wyoming entered a new position worth around $31,000 during the same quarter.

EverSource Wealth Advisors LLC made significant moves, boosting its holdings by an impressive 998.4%, now owning 703 shares with a value of about $32,000. In the third quarter, Quarry LP purchased a new position in LivaNova worth approximately $36,000, while UMB Bank n.a. increased its stake by 63.0%, owning 792 shares valued at $41,000.

Institutional investors and hedge funds collectively own 97.64% of LivaNova’s stock, indicating strong institutional confidence in the company’s future prospects.

About LivaNova

Based in London, United Kingdom, and Houston, Texas, LivaNova plc is a global medical technology company focused on developing and manufacturing innovative products and therapies for the cardiac surgery and neuromodulation markets. The company serves over 100 countries, emphasizing advancements in patient care through innovations in heart-lung bypass, cardiac preservation, circulatory support, and neurostimulation therapies.

The cardiac surgery division offers a wide range of products used in cardiopulmonary bypass procedures, including oxygenators, heart-lung machines, arterial filters, cannulae, and sutureless heart valves.

As LivaNova continues to attract attention from analysts and institutional investors alike, its upward trajectory in the market seems poised for further examination in the coming months.